이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

3SBio 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jing Lou

최고 경영자

CN¥4.9m

총 보상

CEO 급여 비율	26.2%
CEO 임기	18yrs
CEO 소유권	2.4%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jing Lou 의 보수는 3SBio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥5m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥4m	CN¥1m	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥4m	CN¥932k	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥934m
Dec 31 2020	CN¥4m	CN¥432k	CN¥836m
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥194m	CN¥432k	CN¥974m
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥6m	CN¥432k	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥996m
Dec 31 2017	CN¥5m	CN¥432k	CN¥935m

보상 대 시장: Jing 의 총 보상 ($USD 698.33K )은 Hong Kong 시장( $USD 518.33K ).

보상과 수익: Jing 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jing Lou (61 yo)

18yrs

테뉴어

CN¥4,896,000

보상

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou is Directo...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jing Lou	Co-Founder	18yrs	CN¥4.90m	2.4% CN¥ 387.9m
Dongmei Su	Senior VP & Executive Director	12.3yrs	CN¥1.47m	1.04% CN¥ 167.5m
Tianruo Pu	Independent Non-Executive Director	9.3yrs	CN¥270.00k	데이터 없음
Jiaoe Zhang	Non-Executive Director	less than a year	데이터 없음	0.55% CN¥ 88.6m
Hoi Ti Yang	Independent Non-Executive Director	3.3yrs	CN¥270.00k	데이터 없음
Joo Yeow Ng	Independent Non-Executive Director	2.7yrs	CN¥270.00k	데이터 없음

6.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 1530 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

3SBio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Co-Founder recently bought HK$1.5m worth of stock

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

Recent updates

Investor sentiment improves as stock rises 22%

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 1H 2023)

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Mandi Foam of 3SBio Inc. Approves for Market Launch

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021)

Now 22% undervalued

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

3SBio Inc., Annual General Meeting, Jun 22, 2022

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

3SBio Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

3Sbio Inc. Announces Completion the Enrolment of Subjects for Phase Ii Clinical Study

New 90-day high: HK$8.42

3SBio Inc. Provides Update on License Agreement with AstraZeneca and Hongkong Sansheng

New 90-day high: HK$7.81

New 90-day low: HK$7.06

3Sbio Inc. Receives Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212

New 90-day low: HK$7.19

New 90-day low: HK$8.13

First half earnings released

New 90-day low: HK$8.22

3SBio Inc. to Report First Half, 2020 Results on Aug 17, 2020

New 90-day low - HK$8.98

First half earnings released

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령